BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Go back to BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 66.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.43 | 52 Week High | $108.96 | |||
| Open | $66.43 | 52 Week Low | $62.12 | |||
| Day High | $66.43 | P/E | N/A | |||
| Day Low | $66.43 | EPS | $-1.27 | |||
| Volume | 264 | |||||
| (NASDAQ: INZY) | Delayed: 4.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.00 | 52 Week High | $ | |||
| Open | $4.00 | 52 Week Low | $ | |||
| Day High | $4.00 | P/E | N/A | |||
| Day Low | $4.00 | EPS | $ | |||
| Volume | 2,451 | |||||
